Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04321993
Recruitment Status : Recruiting
First Posted : March 26, 2020
Last Update Posted : July 24, 2020
Sponsor:
Collaborators:
Nova Scotia Health Authority
Dalhousie University
Information provided by (Responsible Party):
Lisa Barrett, Nova Scotia Health Authority

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Investigational medications adjunct to clinical standard of care treatment will be assessed to evaluate safety and effectiveness as an anti-COVID-19 treatment. All hospitalized persons with moderate to severe COVID-19 disease that meet eligibility criteria will be offered participation.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Baricitinib (janus kinase inhibitor) Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
Actual Study Start Date : April 17, 2020
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Baricitinib

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Baricitinib Drug: Baricitinib (janus kinase inhibitor)
Baricitinib 2 mg po daily for 10 days
No Intervention: Clinical standard of care


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Clinical status of subject at day 15 (on a 7 point ordinal scale). [ Time Frame: Up to 15 days ]
    1. Not hospitalized, no limitations on activities
    2. Not hospitalized, limitation on activities;
    3. Hospitalized, not requiring supplemental oxygen;
    4. Hospitalized, requiring supplemental oxygen;
    5. Hospitalized, on non-invasive ventilation or high flow oxygen devices;
    6. Hospitalized, on invasive mechanical ventilation or ECMO;
    7. Death.


Secondary Outcome Measures :
  1. Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180. [ Time Frame: Up to 180 days ]
    1. Not hospitalized, no limitations on activities
    2. Not hospitalized, limitation on activities;
    3. Hospitalized, not requiring supplemental oxygen;
    4. Hospitalized, requiring supplemental oxygen;
    5. Hospitalized, on non-invasive ventilation or high flow oxygen devices;
    6. Hospitalized, on invasive mechanical ventilation or ECMO;
    7. Death.

  2. Length of time to clinical improvement [ Time Frame: Up to 29 days ]
    Time to clinical improvement is defined as the time to normalization of respiratory rate, fever, and oxygen saturation, and alleviation of cough within 72 hours.

  3. Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29 [ Time Frame: Up to 29 days ]
  4. Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment [ Time Frame: Up to 24 weeks ]
  5. Length of time to clinical progression [ Time Frame: Up to 29 days ]
    Time to clinical progression, defined as the time to death, mechanical ventilation, or ICU admission

  6. Cause of death (if applicable) [ Time Frame: Up to 24 weeks ]
  7. Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean) [ Time Frame: Up to 29 days ]
  8. Length of time to normalization of fever [ Time Frame: Up to 29 days ]
    Fever normalization as defined by: Temperature < 36.6 °C armpit, < 37.2 °C oral, or < 37.8 °C rectal sustained for minimum 24 hours

  9. Length of time to normalization of oxygen saturation [ Time Frame: Up to 29 days ]
    Oxygen normalization as defined by: peripheral capillary oxygen saturation (Sp02) > 94% sustained minimum 24 hours.

  10. Duration of supplemental oxygen (if applicable) [ Time Frame: Up to 29 days ]
  11. Duration of mechanical ventilation (if applicable) [ Time Frame: Up to 29 days ]
  12. Duration of hospitalization [ Time Frame: Up to 29 days ]
  13. Adverse events [ Time Frame: Up to 180 days ]

Other Outcome Measures:
  1. Global and SARS-CoV-2-specific immune responses before, during and after intervention and in standard of care treatment arm [ Time Frame: Up to 180 days ]
  2. Percent of subjects with SARS-CoV-2 detectable in blood at days 3, 5, 8, 11, 15, 29 and 180. [ Time Frame: Up to 180 days ]
  3. Quantitative SARS-CoV-2 viral load in blood at days 3, 5, 8, and 11, 15, 29, and 180. [ Time Frame: Up to 180 days ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years or older
  • Moderate to severe COVID-19 associated disease as defined by the WHO
  • Hospitalized patient
  • Willing and able to provide written informed consent prior to performing study procedures
  • Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay
  • Illness of any duration, and at least one of the following: Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or Clinical assessment (evidence of rales/crackles on exam) AND SpO2 ≤ 94% on room air, or Require mechanical ventilation and/or supplemental oxygen.
  • Febrile defined as temperature ≥ 36.6 °C armpit, ≥ 37.2 °C oral, or ≥ 37.8 °C rectal documented within 48 hours of consent

Exclusion Criteria:

  • Participation in any other clinical trial of an experimental treatment for COVID-19
  • Concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2 is prohibited < 24 hours prior to study medication initiation
  • SOFA >10
  • Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN)
  • Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30)
  • Pregnant women or women who are breastfeeding
  • Immunocompromised patients taking medication upon screening
  • Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04321993


Contacts
Layout table for location contacts
Contact: Barbara Goodall (902) 292-0132 barbara.goodall@nshealth.ca
Contact: Lisa Barrett (902) 473-6446 lisa.barrett@nshealth.ca

Locations
Layout table for location information
Canada, Nova Scotia
Nova Scotia Health Authority Recruiting
Halifax, Nova Scotia, Canada, B3H 1V7
Contact: Lisa Barrett, MD       lisa.barrett@nshealth.ca   
Contact: Barbara Goodall       barbara.goodall@nshealth.ca   
Sponsors and Collaborators
Lisa Barrett
Nova Scotia Health Authority
Dalhousie University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Lisa Barrett, Clinician Scientist, Nova Scotia Health Authority
ClinicalTrials.gov Identifier: NCT04321993    
Other Study ID Numbers: SAIL-004
First Posted: March 26, 2020    Key Record Dates
Last Update Posted: July 24, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lisa Barrett, Nova Scotia Health Authority:
COVID
coronavirus
SARS-CoV-2
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
 Janus Kinase Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action